NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 25th Annual Global Investment Conference, being held at the Lotte New York Palace Hotel, in New York City on September 11 - 13, 2023. The fireside chat is scheduled to take place on Monday, September 11, 2023, at 10:30 AM ET.
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received approval from the U.S. FDA for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as European Commission (EC) approval for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and on LinkedIn.
CONTACT:
| Investor Relations: |
| Email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Telephone: 1.877.575.TGTX (8489), Option 4 |
| Media Relations: |
| Email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Telephone: 1.877.575.TGTX (8489), Option 6 |
| Last Trade: | US$38.92 |
| Daily Change: | 1.83 4.93 |
| Daily Volume: | 1,598,297 |
| Market Cap: | US$6.180B |
May 05, 2025 April 08, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
